Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Education » Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

  • October 9, 2024

NECA have been involved in the development of Guidelines for “ Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs” which is now published and has been endorsed by the Commonwealth Neuroendocrine Tumour Collaboration and the North American Neuroendocrine Tumour Society.

After an extensive literature review, multidisciplinary in person workshop and Delphi methos  – the quality of evidence and strength of recommendations were determined using the Grading of Recommendations, Assessment, Development and Evaluations framework.  The study results suggest that select factors have sufficient evidence to inform care in GEP-NENs, but the evidence for most biomarkers is weak.

Read the Published article here along with the supplement

Share this post

Recent posts

Announcing our First Patient Ambassador – Cassie Miller

June 17, 2025

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

June 16, 2025

2025 Impact Report

June 16, 2025

Be the Voice for NET Patients in WA – Join Our CAG Team

June 10, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPrevious12th INCA Global NET Cancer Advocate Summit
NextAUS-NET October 2024 updateNext

Related Posts

Announcing our First Patient Ambassador – Cassie Miller

NeuroEndocrine Cancer Australia is proud to welcome Cassie Miller from Queensland as our very first official Patient Ambassador. Cassie was 36 when she was diagnosed

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

NeuroEndocrine Cancer Australia (NECA) was proud to attend the 5th Neuroendocrine Tumour (NET) Preceptorship held 13 & 14th June at Peter MacCallum Cancer Centre in

2025 Impact Report

This year, NeuroEndocrine Cancer Australia continued to expand our reach and impact thanks to the incredible support of our community. Click below to read the

Be the Voice for NET Patients in WA – Join Our CAG Team

Call out for a consumer advisory representative from Western Australia (voluntary position) Are you from Western Australia? Have you experienced a diagnosis of a Neuroendocrine

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin